eCite Digital Repository

Monoclonal antibody therapy in cancer: when two is better (and considerably more expensive) than one

Citation

Peterson, GM and Thomas, J and Yee, KC and Kosari, S and Naunton, M and Olesen, IH, Monoclonal antibody therapy in cancer: when two is better (and considerably more expensive) than one, Journal of Clinical Pharmacy and Therapeutics, 43, (6) pp. 925-930. ISSN 0269-4727 (2018) [Contribution to Refereed Journal]

Copyright Statement

2018 John Wiley & Sons Ltd

DOI: doi:10.1111/jcpt.12750

Abstract

What is known and objective: It is 20 years since the US Food and Drug Administration approved the first successful monoclonal anticancer antibody, trastuzumab. The therapeutic utility of monoclonal antibodies in cancer is often limited by partial clinical responses and the development of tumour resistance. An expanding strategy, to be reviewed here, to overcome the limited response and resistance to monotherapy utilizes concurrent treatment with two synergistic monoclonal antibodies.

Comment: Key examples include two monoclonal antibodies, each engaging a distinct site of human epidermal growth factor receptor 2 (HER2), in the treatment of breast cancer and a combination of antibodies to two distinct T-cell antigens for the treatment of melanoma. Here, we provide an overview of the rationale and evidence for using selected monoclonal antibodies in combination for treating some cancers, along with potential hazards, especially autoimmune-related toxicities.

What is new and conclusion: Thorough research, the development of panels of biomarkers and individualization of therapy will be necessary to optimize the use of these combinations and minimize the substantial risk of overstimulating the immune system.

Item Details

Item Type:Contribution to Refereed Journal
Keywords:cancer, combination, immune checkpoint, monoclonal antibody, toxicity
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Clinical Pharmacology and Therapeutics
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cancer and Related Disorders
UTAS Author:Peterson, GM (Professor Gregory Peterson)
ID Code:129282
Year Published:2018
Web of Science® Times Cited:3
Deposited By:Pharmacy
Deposited On:2018-11-20
Last Modified:2019-12-23
Downloads:0

Repository Staff Only: item control page